Skip to main content
Premium Trial:

Request an Annual Quote

Sloan-Kettering Joins Sigma-Aldrich's RNAi Partnership Program

NEW YORK (GenomeWeb News) – Memorial Sloan-Kettering Cancer Center has joined Sigma-Aldrich’s RNAi Partnership Program, the St. Louis, Mo.-based firm said today.
 
Sigma-Aldrich said that members of the program gain access to products in its functional genomics portfolio including shRNA libraries developed by the RNAi Consortium that target more than 15,000 human genes and 15,000 mouse genes. Sigma-Aldrich is a member of the RNAi Consortium.
 
The RNAi Consortium was established by the Broad Institute in 2004. The public/private alliance of RNAi researchers is developing genome-scale sets of virally expressed shRNAs targeting mouse and human genes.
 
New York City-based Sloan-Kettering joins a list of academic and other research institutes including the Cleveland Clinic, the Harvard Stem Cell Institute, Washington University of St. Louis, Princeton University, the Wistar Institute, and Rutgers University, as members of the program.

The Scan

Not Immediately Told

The US National Institutes of Health tells lawmakers that one of its grantees did not immediately report that it had developed a more infectious coronavirus, Science says.

Seems Effective in Kids

The Associated Press reports that the Pfizer-BioNTech SARS-CoV-2 vaccine for children appears to be highly effective at preventing symptomatic disease.

Intelligence Warning on Bioeconomy Threats

US intelligence warns over China's focus on technologies and data related to the bioeconomy, the New York Times reports.

PLOS Papers on Campylobacteriosis Sources, Inherited Retinal Dystrophies, Liver Cancer Prognosis

In PLOS this week: approach to uncover source of Campylobacteriosis, genetic risk factors for inherited retinal dystrophies, and more.